Gilead's deep discounts fuel investor worries about drug pricing

Feb 4 (Reuters) - Investors reassessed their growth expectations for the red-hot biotechnology sector on Wednesday after Gilead Sciences Inc warned of steep drug discounts, but a number of fund managers seemed prepared to stick with the stocks.